TOKYO, Dec. 1, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Etalanetug is designed to bind to the microtubule- binding region (MTBR) of tau protein and prevent the seeding and propagation of tau pathology. Anti-tau therapeutic antibody, etalanetug, reduces the novel biomarker plasma eMTBR-tau243 in patien ...